Dr. Lu is an Investor at Yosemite, an oncology-focused firm spun out of Emerson Collective Health. Dr. Lu specializes in company creation and early-stage investments of breakthrough technologies across therapeutics, diagnostics, and tools & reagents in Oncology. She brings ~20 years of life science experience across R&D, business development, corporate strategy and operations, and venture investment.

Prior to Yosemite, Dr. Lu was Strategy & Operations Director at Amgen US, responsible for driving and executing key decisions for ~50% of Amgen’s business. At Amgen, Dr. Lu led large cross-functional initiatives that transformed business performance, successfully commercialized new products, and innovated customer engagement models. Before Amgen, she spent 4 years at McKinsey & Company helping numerous pharmaceutical companies solve challenges including R&D strategy and operations, business development, and commercialization strategies.

Dr. Lu has deep scientific expertise in immuno-oncology and therapeutic protein engineering. She completed her undergraduate education in Chemical Biology at UC Berkeley with highest honor, Ph.D. in Chemistry at California Institute of Technology and immuno-oncology postdoctoral fellowship at Harvard University.